Lilly's weekly insulin succeeds in late-stage studies
Send a link to a friend
[May 16, 2024]
(Reuters) -Eli Lilly said on Thursday that its once-weekly
insulin efsitora met the main goals in two late-stage trials evaluating
it in people with type 2 diabetes.
Lilly said that efsitora was equally safe and effective among adults who
have previously not been on insulin therapy.
In both the studies, efsitora showed non-inferior reduction in blood
sugar levels in patients, compared to the most commonly used daily
long-acting insulins globally.
One of the studies also evaluated the weekly, long-acting insulin in
patients who are currently using and not using GLP-1 therapies, Lilly
said.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
[to top of second column]
|
![](../images/051624PIX/health28.jpg)
Lilly Biotechnology Center is shown in San Diego, California, U.S.
March 1, 2023 after Eli Lilly and Co on Wednesday said it will cut
list prices by 70% for its most commonly prescribed insulin
products, Humalog and Humulin, beginning from the fourth quarter of
this year. REUTERS/Mike Blake
![](http://archives.lincolndailynews.com/2024/May/16/images/ads/current/graue_lda_BUICKENCORE4176_051324.jpg)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |